Pyrazolylmethy Heteroaryl Derivatives
    3.
    发明申请
    Pyrazolylmethy Heteroaryl Derivatives 审中-公开
    吡唑基甲基杂芳基衍生物

    公开(公告)号:US20080004269A1

    公开(公告)日:2008-01-03

    申请号:US11718528

    申请日:2005-11-01

    摘要: Compounds of Formula (I) are provided, as are methods for their preparation. The variables W, X, Y, Z, R5, R8 and Ar in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptorsin vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).

    摘要翻译: 提供式(I)的化合物,以及它们的制备方法。 上式定义了上式中的变量W,X,Y,Z,R 5,R 8和Ar。 这样的化合物可用于在体内或体外调节配体与GABA A A受体的结合,并且特别可用于治疗人类中的各种中枢神经系统(CNS)障碍,驯养的伴侣动物和 牲畜。 本文提供的化合物可以单独施用或与一种或多种其它CNS剂组合施用,以增强其它CNS剂的作用。 还提供了用于治疗这种病症的药物组合物和方法,以及使用这种配体检测GABA A受体的方法(例如,受体定位研究)。

    Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands
    4.
    发明申请
    Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands 有权
    咪唑并 - 嘧啶和三唑并嘧啶:苯并二氮杂受体配体

    公开(公告)号:US20050038043A1

    公开(公告)日:2005-02-17

    申请号:US10898690

    申请日:2004-07-23

    IPC分类号: C07D487/04 A61K31/519

    CPC分类号: C07D487/04

    摘要: Compounds of Formula I are provided, as are methods for their preparation. The variables Z1, Z2, Z3, R4, R5, R6, R7, R8 and Ar in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).

    摘要翻译: 提供了式I化合物,以及其制备方法。 上述式中的变量Z1,Z2,Z3,R4,R5,R6,R7,R8和Ar定义如下。 这样的化合物可用于在体内或体外调节配体与GABA A受体的结合,并且特别可用于治疗人,驯养的伴侣动物和家畜中的各种中枢神经系统(CNS)障碍。 本文提供的化合物可以单独施用或与一种或多种其它CNS剂组合施用,以增强其它CNS剂的作用。 还提供了用于治疗这种病症的药物组合物和方法,以及使用这种配体检测GABA A受体的方法(例如受体定位研究)。

    Substituted biaryl piperazinyl-pyridine analogues
    10.
    发明申请
    Substituted biaryl piperazinyl-pyridine analogues 有权
    取代的联芳基哌嗪基 - 吡啶类似物

    公开(公告)号:US20060122394A1

    公开(公告)日:2006-06-08

    申请号:US11204202

    申请日:2005-08-13

    IPC分类号: C07D403/14

    摘要: Substituted biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptors activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

    摘要翻译: 提供了下式的取代的联芳基哌嗪基 - 吡啶类似物:其中变量如本文所述。 这样的化合物是可用于在体内或体外调节特异性受体活性的配体,并且特别可用于治疗与人,驯养的伴侣动物和家畜中的病理受体激活相关的病症。 还提供了使用这些化合物治疗这种病症的药物组合物和方法,以及使用这些配体进行受体定位研究的方法。